Filtered By:
Condition: Fatty Liver Disease (FLD)
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 185 results found since Jan 2013.
Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathway
CONCLUSION: Metformin protects against lipid formation in ALD by activating the LKB1/AMPK/ACC axis.PMID:35733070 | DOI:10.1007/s11033-022-07610-y
Source: Molecular Biology Reports - June 22, 2022 Category: Molecular Biology Authors: Fotian Xie Yuanming Zhong Dongmei Wang Kwok Fai So Jia Xiao Yi Lv Source Type: research
Upregulation of hepatic CD36 via glucocorticoid receptor activation contributes to dexamethasone-induced liver lipid metabolism disorder in mice
Toxicol Lett. 2022 May 16:S0378-4274(22)00091-1. doi: 10.1016/j.toxlet.2022.05.003. Online ahead of print.ABSTRACTGlucocorticoids such as dexamethasone (DEX) are widely prescribed to treat numerous conditions and diseases. However, glucocorticoid-induced liver lipid metabolism disorder, even nonalcoholic fatty liver disease, has caused extensive attention. Since fatty acid transporters such as CD36 and FATP play crucial roles in hepatic fatty acid uptake, this work examined their potential involvement in DEX-induced liver lipid accumulation. Chronic DEX administration (1-5mg/kg/day over 28 days) induced hepatic lipid accum...
Source: Toxicology Letters - May 19, 2022 Category: Toxicology Authors: Mingyang Chen Mengru Bai Yaodong Yi Shuanghui Lu Jun Luo Ping Li Hengbin Zhang Huidi Jiang Hui Zhou Source Type: research
A fluorinated peptide with high serum- and lipid-tolerence for the delivery of siRNA drugs to treat obesity and metabolic dysfunction
Biomaterials. 2022 Apr 28;285:121541. doi: 10.1016/j.biomaterials.2022.121541. Online ahead of print.ABSTRACTObesity is the major risk factor for metabolic diseases such as fatty liver, hyperlipidemia and insulin resistance. Beige fat has been recognized as a therapeutic target considering its great potential to burn energy. Since the evolutionary discovery of RNA interference and its utilization for gene knockdown in mammalian cells, a remarkable progress has been achieved in siRNA-based therapeutics. However, efficient delivery of siRNA into adipose tissues or differentiated adipocytes is challenging due to high lipid co...
Source: Biomaterials - May 9, 2022 Category: Materials Science Authors: Jin Qiu Qianqian Fan Sainan Xu Dongmei Wang Juntong Chen Sainan Wang Tianhui Hu Xinran Ma Yiyun Cheng Lingyan Xu Source Type: research
Abietic acid alleviates endoplasmic reticulum stress and lipid accumulation in human primary hepatocytes through the AMPK/ORP150 signaling
This study investigated the impacts of AA on ER stress and steatosis in in vitro obesity models. We found that Treatment with AA reduced lipid deposition and lipogenesis-related proteins expression in human primary hepatocytes. Augmented expression of ER stress markers (phospho-eukaryotic initiation factor-2α (eIF2α) and C/EBP homologous protein (CHOP)) in palmitate-treated hepatocytes were reversed by AA treatment. Further, AA treatment increased the expression of phospho-AMPK and oxygen-regulated protein 150 (ORP150) in hepatocytes. siRNA-associated knockdown of AMPK or ORP150 expression reduced the effects of AA on no...
Source: Biochemical and Biophysical Research communications - April 10, 2022 Category: Biochemistry Authors: Tae Woo Jung Ju-Cheol Jeong Seung Yeon Park Wonjun Cho Heeseung Oh Hyun Jung Lee Ahmet Hacimuftuoglu A M Abd El-Aty Joon Seok Bang Ji Hoon Jeong Source Type: research
Nudix hydrolase NUDT19 regulates mitochondrial function and ATP production in murine hepatocytes
This study is the first to describe Nudt19 as regulator of hepatic lipid metabolism and potential mediator of NAFLD and T2D development.PMID:35367353 | DOI:10.1016/j.bbalip.2022.159153
Source: Biochimica et Biophysica Acta - April 3, 2022 Category: Biochemistry Authors: Sarah G örigk D Margriet Ouwens Tanja Kuhn Delsi Altenhofen Christian Binsch Mareike Damen Jenny Minh-An Khuong Katharina Kaiser Birgit Knebel Heike Vogel Annette Sch ürmann Alexandra Chadt Hadi Al-Hasani Source Type: research
Valdecoxib attenuates lipid-induced hepatic steatosis through autophagy-mediated suppression of endoplasmic reticulum stress
This study investigated the effects of VAL on lipid accumulation and lipogenesis in human primary hepatocytes. Treatment with VAL suppressed lipid accumulation and expressions of lipogenic genes, such as processed sterol regulatory element binding proteins (SREBP1) and stearoyl-CoA desaturase-1 (SCD1) in palmitate-treated hepatocytes. Furthermore, VAL ameliorated dose-dependently palmitate-induced ER stress markers. Treatment of hepatocytes with VAL increased AMPK phosphorylation and SIRT6 expression. siRNA-mediated suppression of AMPK or SIRT6 abolished the effects of VAL on lipid accumulation, lipogenesis, and endoplasmi...
Source: Biochemical Pharmacology - March 31, 2022 Category: Drugs & Pharmacology Authors: Seung Yeon Park Wonjun Cho A M Abd El-Aty Ahmet Hacimuftuoglu Ji Hoon Jeong Tae Woo Jung Source Type: research
Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine
Conclusion, high fat and TMA could induce the expression of FMO1 and its metabolite TMAO. When FMO1 is silenced, the effects of high fat and TMA on TMAO are blocked. And the role of TMAO in NAFLD may be through the activation of UPR.PMID:35065293 | DOI:10.1016/j.bbrc.2022.01.060
Source: Biochemical and Biophysical Research communications - January 22, 2022 Category: Biochemistry Authors: Chunxia Shi Maohua Pei Yao Wang Qian Chen Pan Cao Luyi Zhang Jin Guo Wei Deng Luwen Wang Xun Li Zuojiong Gong Source Type: research
Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling
This study not only identified a new skeleton of FFA4 agonists, but also demonstrated that FFA4 signal was accounting for the protective effects of UDCA in the NAFLD treatment.PMID:35033554 | DOI:10.1016/j.ejphar.2022.174760
Source: European Journal of Pharmacology - January 16, 2022 Category: Drugs & Pharmacology Authors: Fangfang Xu Jun Wang Pan Wang Tao Hou Han Zhou Yaopeng Zhao Jixia Wang Yanfang Liu Xinmiao Liang Source Type: research
